Works by Paracha, Noman

Results: 15

Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling.

Published in:

Medical Decision Making, 2022, v. 42, n. 2, p. 194, doi. 10.1177/0272989X211026288

By:

Kuehne, Felicitas;
Rochau, Ursula;
Paracha, Noman;
Yeh, Jennifer M.;
Sabate, Eduardo;
Siebert, Uwe

Publication type:

Article

Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.

Published in:

2020

By:

Marine, Sivignon;
Stéphane, Roze;
Nicolas, Plommet;
Felizzi, Federico;
Paracha, Noman;
Benjamin, Mazaleyrat;
Perol, Maurice;
Sivignon, Marine;
Roze, Stéphane;
Plommet, Nicolas;
Mazaleyrat, Benjamin

Publication type:

journal article

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

Published in:

2019

By:

Ondhia, Umang;
Conter, H. J.;
Owen, Scott;
Zhou, Anna;
Nam, Julian;
Singh, Sumeet;
Abdulla, Ahmed;
Chu, Paula;
Felizzi, Federico;
Paracha, Noman;
Sangha, Randeep

Publication type:

journal article

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.

Published in:

Oncology, 2022, v. 100, n. 2, p. 124, doi. 10.1159/000519767

By:

Briggs, Andrew;
Paracha, Noman;
Rosettie, Katherine;
Upton, Alexander;
Bokemeyer, Carsten;
Lassen, Ulrik;
Sullivan, Sean D.

Publication type:

Article

Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).

Published in:

2022

By:

Paracha, Noman;
Hudson, Pollyanna;
Mitchell, Stephen;
Sutherland, C. Simone

Publication type:

Correction Notice

Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.

Published in:

PharmacoEconomics, 2022, v. 40, n. 1, p. 39, doi. 10.1007/s40273-021-01115-5

By:

Sutherland, C. Simone;
Hudson, Pollyanna;
Mitchell, Stephen;
Paracha, Noman

Publication type:

Article

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.

Published in:

PharmacoEconomics, 2022, v. 40, n. 1, p. 11, doi. 10.1007/s40273-021-01105-7

By:

Paracha, Noman;
Hudson, Pollyanna;
Mitchell, Stephen;
Sutherland, C. Simone

Publication type:

Article

Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).

Published in:

PharmacoEconomics, 2022, v. 40, n. 1, p. 69, doi. 10.1007/s40273-021-01095-6

By:

Paracha, Noman;
Hudson, Pollyanna;
Mitchell, Stephen;
Sutherland, C. Simone

Publication type:

Article

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom.

Published in:

PharmacoEconomics, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s40273-021-01092-9

By:

Lo, Siu Hing;
Gorni, Ksenija;
Sutherland, C. Simone;
Martí, Yasmina;
Lloyd, Andrew;
Paracha, Noman

Publication type:

Article

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.

Published in:

Cancers, 2022, v. 14, n. 7, p. 1793, doi. 10.3390/cancers14071793

By:

Garcia-Foncillas, Jesus;
Bokemeyer, Carsten;
Italiano, Antoine;
Keating, Karen;
Paracha, Noman;
Fellous, Marc;
Marian, Marisca;
Fillbrunn, Mirko;
Gao, Wei;
Ayyagari, Rajeev;
Lassen, Ulrik

Publication type:

Article

Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.

Published in:

2016

By:

Paracha, Noman;
Thuresson, Per-Olof;
Moreno, Santiago G.;
MacGilchrist, Katherine S.

Publication type:

journal article

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.

Published in:

Oncologist, 2023, v. 28, n. 5, p. e242, doi. 10.1093/oncolo/oyad005

By:

Stenzinger, Albrecht;
Cuffel, Brian;
Paracha, Noman;
Vail, Eric;
Garcia-Foncillas, Jesus;
Goodman, Clifford;
Lassen, Ulrik;
Vassal, Gilles;
Sullivan, Sean D

Publication type:

Article

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.

Published in:

Breast Cancer Research & Treatment, 2020, v. 180, n. 3, p. 597, doi. 10.1007/s10549-020-05577-7

By:

Paracha, Noman;
Reyes, Adriana;
Diéras, Véronique;
Krop, Ian;
Pivot, Xavier;
Urruticoechea, Ander

Publication type:

Article

Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.

Published in:

2018

By:

Paracha, Noman;
Abdulla, Ahmed;
MacGilchrist, Katherine S.

Publication type:

journal article

Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.

Published in:

2017

By:

Griffiths, Alison;
Paracha, Noman;
Davies, Andrew;
Branscombe, Neil;
Cowie, Martin;
Sculpher, Mark;
Cowie, Martin R

Publication type:

journal article